PT Bundamedik TbkISX:BMHS -1.65%61 ROE % is 0.01% as of Mar. 2026, which is 100% below its 10-year median of 2.31. GuruFocus rates ISX:BMHS with a GF Score™ of 61/100 and a GF Value™ of Rp304.24 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 625 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks worse than 67.2% on this metric.
The historical rank and industry rank for PT Bundamedik Tbk's ROE % or its related term are showing as below:
ISX:BMHS'
s ROE % Range Over the Past 10 Years
Min: 0.47 Med: 2.31 Max: 16.71
Current: 0.51
During the past 8 years, PT Bundamedik Tbk's highest ROE % was 16.71%. The lowest was 0.47%. And the median was 2.31%.
ISX:BMHS's ROE % is ranked worse than 67.2% of 625
companies
in the Healthcare Providers & Services industry
Industry Median: 5.84
vs ISX:BMHS: 0.51
PT Bundamedik Tbk (ISX:BMHS) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
PT Bundamedik Tbk ROE % Related Terms
PT Bundamedik Tbk ROE % Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's ROE % distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
PT Bundamedik Tbk (ISX:BMHS) has a ROE % of 0.01% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Bundamedik Tbk and its competitors. This is 100% below median its historical median of 2.31. Over the past decade, PT Bundamedik Tbk's ROE % has ranged from 0.47 to 16.71. According to the industry distribution chart, PT Bundamedik Tbk ranks #420 out of 625 companies in the Healthcare Providers & Services industry, placing it in the top 67.2%.
Is PT Bundamedik Tbk's ROE % too high?
PT Bundamedik Tbk's current ROE % of 0.01% is 100% below median its 10-year median of 2.31. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 16.71. The Healthcare Providers & Services industry median ROE % is 5.84. PT Bundamedik Tbk's value of 0.01% is 99.8% below this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #420 out of 625 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #420 out of 625 companies for ROE %. This places PT Bundamedik Tbk in the lower half of its industry. The industry median ROE % is 5.84. PT Bundamedik Tbk's value of 0.01% is 99.8% below this benchmark. Historically, PT Bundamedik Tbk's own ROE % has ranged from 0.47 to 16.71 over the past decade. While the company's 10-year median is 2.31 vs. the industry median of 5.84, PT Bundamedik Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.84, based on 625 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current ROE % of 0.01% is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current ROE % is 0.01%, which is 100% below median its own 10-year median of 2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Possible Value Trap. The stock's GF Value™ is Rp304.24, compared to a current price of Rp179.00 — trading 41.2% below its estimated fair value. The current ROE % is 0.01%, which is 100% below median its 10-year median of 2.31 and 99.8% below the Healthcare Providers & Services industry median of 5.84. PT Bundamedik Tbk's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current ROE % is 0.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp179.00 is trading 41.2% below its estimated GF Value™ of Rp304.24.
GuruFocus considers PT Bundamedik Tbk to be Possible Value Trap.
Key valuation signals for ISX:BMHS:
ROE %: 0.01% (100% below median its 10-year median of 2.31)
GF Value™: Rp304.24 vs. price of Rp179.00 (41.2% below fair value)
Industry Position: 99.8% below the Healthcare Providers & Services median (#420 of 625)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
61GF Score
Get the complete analysis for ISX:BMHS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
